Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Authors' Reply to the Comments of Joshua Fogel and Abhinav Saxena on Our Paper.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Immunomodulatory Role of Complement Proteins in the Neuropathology Associated with Opiate Abuse and HIV-1 Co-Morbidity.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018 02 08; 378(6):518-528.
View in:
PubMed
subject areas
Adult
Aged
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Bortezomib
Disease-Free Survival
Female
Follow-Up Studies
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Melphalan
Middle Aged
Multiple Myeloma
Prednisone
Survival Rate
authors with profiles
Andrzej Jakubowiak